15 February 2026 23:00 UTC · European Commission · EU Commission Press Release · Source · Email X Link

European Commission closes antitrust probe after Edwards withdraws UPIP

Key points

Investigation closed after withdrawal of UPIP
Closure not a finding of compliance with EU competition rules

TL;DR

European Commission says it closed its antitrust investigation after Edwards Lifesciences withdrew its Global Unilateral Pro-Innovation (Anti-Copycatting) Policy (UPIP).
The Commission notes the UPIP has been removed from Edwards Lifesciences' website and is no longer applicable.
The Commission states the closure is not a finding that the conduct complied with EU competition rules.

Original text

European Commission - Press release Commission closes antitrust investigation following the withdrawal by Edwards Lifesciences of its disputed company policy Brussels, 16 February 2026 The European Commission has decided to close its antitrust investigation into allegedly anticompetitive behaviour by Edwards Lifesciences, a producer of medical devices for cardiovascular applications. The closure of the investigation follows the company's withdrawal of its so-called Global Unilateral Pro-Innovation (Anti-Copycatting) Policy ('UPIP'). Hence, the UPIP is no longer applicable and has been removed from the company's website. In September 2023 , the Commission carried out unannounced inspections at Edwards Lifesciences' premises in the EU. The purpose of the inspections was to investigate whether conduct by Edwards Lifesciences could breach EU antitrust rules that prohibit abuses of a dominant market position ( Article 102 of the Treaty on the Functioning of the European Union). The Commission has in particular been investigating whether Edwards Lifesciences, through its UPIP, may have limited physicians' freedom to participate in clinical trials and other scientific and educational activities sponsored or supported by a competing manufacturer of Transcatheter Aortic Valve Implantation ('TAVI') devices. By limiting that competitor's access to important services which assisted their research on medical devices, such as input derived from said physicians, Edwards Lifesciences could have made it more difficult for such a competitor to establish its products in the European Economic Area. After thorough analysis and careful assessment of all evidence gathered and in light of Edwards Lifesciences' withdrawal of the UPIP, the Commission has concluded that the investigated concerns have been addressed and further action is no longer considered a priority at EU level. The closure of the investigation is not a finding that the conduct in question complied with EU competition rules. Background Edwards Lifesciences is a medical technology company headquartered in the US, which focuses on medical devices for cardiovascular applications. Transcatheter Aortic Valve Implantation procedures make it possible to replace aortic valves with an artificial valve implanted via catheter, thus avoiding putting the patient through a complex open-heart surgery. Edwards Lifesciences' TAVI devices are used to treat aortic stenosis, one of the most common and serious cardiovascular diseases. Cardiovascular diseases are the leading cause of premature death in the EU. On 16 December 2025, the Commission adopted its Safe Hearts Plan , which includes measures to improve prevention, detection and treatment of cardiovascular diseases. For more information More information on the investigation will be available on the Commission's competition website , in the public case register under the case number AT.40755 . IP/26/412 Press contacts: Ricardo CARDOSO (+32 2 29 80100) Paula Clara RITTER-MOSCHUTZ (+32 2 29 64083) General public inquiries: Europe Direct by phone 00 800 67 89 10 11 or by email

Key tags

Topics

Keywords

Stats

Word count: 452

Summary words: 71

Compression: 16%

Boilerplate removed: Yes

Top phrases:

Entities

People

Organizations

Places

Brussels